Cargando…
CCNF is a potential pancancer biomarker and immunotherapy target
BACKGROUND: CCNF catalyzes the transfer of ubiquitin molecules from E2 ubiquitin-conjugating enzymes to target proteins, thereby regulating the G1/S or G2/M transition of tumor cells. Thus far, CCNF expression and its potential as a pancancer biomarker and immunotherapy target have not been reported...
Autores principales: | Wei, Lifang, Li, Huiming, Xiao, Mengjun, Zhou, Cuiling, Liu, Jiliang, Weng, Shilian, Wei, Ruda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164972/ https://www.ncbi.nlm.nih.gov/pubmed/37168372 http://dx.doi.org/10.3389/fonc.2023.1109378 |
Ejemplares similares
-
Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy
por: Cui, Jing, et al.
Publicado: (2022) -
ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC
por: Zhou, Lingyi, et al.
Publicado: (2022) -
Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis
por: Li, Juanni, et al.
Publicado: (2020) -
Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma
por: Xiong, Ye, et al.
Publicado: (2022) -
CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia
por: Williams, Kelly L., et al.
Publicado: (2016)